[4] Enterotoxigenic E. coli (ETEC and EAEC) cause approximately Selleck PR 171 half of TD in Latin America, Africa, South Asia, and the Middle East.[5, 6] It was first shown by Kean[7] that antibiotics can prevent a large proportion of TD. In the 1970s and 1980s, doxycycline and fluoroquinolones were successfully used to prevent TD.[8, 9] A National Institutes of Health (NIH) Consensus Development Conference in 1985, however, discouraged using prophylactic antibiotic treatment because of concern about absorbable antibiotics contributing to the development

of resistance strains.[10] Rifaximin is a non-systemic, gut-selective antibiotic that has activity against enteric bacterial pathogens causing TD in multiple areas of the world.[11, 12] The small study size of previous studies has yielded inconsistent findings. The purpose of this meta-analysis was to integrate all available data to provide a clearer understanding of rifaximin’s efficacy. A systematic search of the literature in PubMed (up to November 2011), the Cochrane Central Register of Controlled Trials (Cochrane Library Issue 4,

October 2011), Embase (up to November 2011), and the Science Citation Index (up to November 2011) was conducted to identify relevant randomized controlled trials (RCTs) for our meta-analysis. In addition, references from the trials were further searched manually to Z-VAD-FMK price identify potentially relevant studies. The following selection criteria were applied: (1) study design: randomized, controlled trial; (2) study population: healthy, adult civilian travelers or military members aged ≥18 years; (3) intervention: prophylactic administration of rifaximin; (4) comparison intervention: placebo; (5) outcome measures: the primary efficacy end point was occurrence of diarrhea during 14 days of treatment with rifaximin or placebo. TD was defined as passage of at least three unformed stools within a 24-hour period plus one or more of the following signs or symptoms

of enteric infection: PD184352 (CI-1040) abdominal pain or cramps, nausea, vomiting, fever (≥37.8°C), fecal urgency, passage of gross blood or mucus in stool, tenesmus, or moderate to severe increase in intestinal gas.[13] Secondary end points included: incidence of the required antibiotic treatment, occurrence of mild diarrhea (MD; defined as a passage of one to two unformed stools during a 24-hour period plus at least one of the described abdominal symptoms for TD), incidence of TD occurring in the 7-day follow-up period, incidence of TD associated with isolation of diarrheagenic E. coli (ie, ETEC, EAEC), TD associated with unidentified pathogens, and any adverse events. Two review authors independently extracted details of randomization methods, blinding of treatments, and outcome assessments. Standardized, detailed forms for extraction of data from the selected trials (Table 1) were developed.